
Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Drugs In Development, 2022, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 23, 10, 20, 3, 66, 19 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Drugs In Development, 2022, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 23, 10, 20, 3, 66, 19 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
332 Pages
- Introduction
- Global Markets Direct Report Coverage
- Osteoporosis – Overview
- Osteoporosis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Osteoporosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteoporosis – Companies Involved in Therapeutics Development
- Abiogen Pharma SpA
- Ablynx NV
- Abreos Biosciences Inc
- Aclaris Therapeutics Inc
- Addpharma Inc
- Aerami Therapeutics Inc
- Affilogic SAS
- AgeX Therapeutics Inc
- Airsea (Taizhou) Pharmaceutical Ltd
- AlphaMab Co Ltd
- Alvotech SA
- Amgen Inc
- Amogen Pharma Pvt Ltd
- Angitia Biopharmaceuticals
- Aryogen Pharmed Co
- Aveta Biomics Inc
- Bainan Biotech ApS
- Beijing Kangleweishi Biotechnology Co Ltd
- Beijing Northland Biotech Co Ltd
- Beryl Therapeutics Inc
- Better Life Pharmaceuticals Inc
- Biocon Ltd
- Bone Biologics Corp
- Cellatoz Therapeutics Inc
- Celltrion Inc
- China NT Pharma Group Co Ltd
- ChoDang Pharm Co Ltd
- Citragen Pharmaceuticals Inc
- CK Regeon Inc
- Clayton Biotechnologies Inc
- Clonz Biotech Pvt Ltd
- Corium Inc
- CSPC Pharmaceutical Group Ltd
- Curexsys GmbH
- Daewoong Pharmaceutical Co Ltd
- Dongkook Pharmaceutical Co Ltd
- Eden Biologics Inc
- Eli Lilly and Co
- Endoceutics Inc
- Enesi Pharma Ltd
- Entera Bio Ltd
- Enteris BioPharma Inc
- Enzene Biosciences Ltd
- Enzo Biochem Inc
- Epygen Biotech Pvt Ltd
- Evgen Pharma Plc
- Fresenius Kabi SwissBioSim GmbH
- Galapagos NV
- Gbiologics Inc
- Gedeon Richter Plc
- Genor BioPharma Co Ltd
- Genu Pharma Co Ltd
- GlycoNex Inc
- GPN Therapeutics Inc
- Haoma Medica Ltd
- Helixmith Co Ltd
- Histide AG
- HNB Therapeutics LLC
- Hualan Biological Engineering Inc
- Huons Global Co Ltd
- IMGENEX India Pvt Ltd
- Immunwork Inc
- InnoPharmaScreen Inc
- Intas Pharmaceuticals Ltd
- Ipsen SA
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Keros Therapeutics Inc
- Kyoto Pharmaceutical Industries Ltd
- Lactocore Inc
- LBL Biotech Corp
- Lead Discovery Center GmbH
- LEXEO Therapeutics LLC
- Link Biologics Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabxience Holding SL
- Max Biopharma Inc
- Merck & Co Inc
- Mesentech Inc
- Mezomax Inc
- Nano Intelligent Biomedical Engineering Corp
- Nanomedic Inc
- NeuClone Pty Ltd
- NovMetaPharma Co Ltd
- Omeros Corp
- Oncosimis Biotech Pvt Ltd
- Ortho Regenics Pvt Ltd
- OssiFi Inc
- Paras Biopharmaceuticals Finland Oy
- PhytoHealth Corp
- Prestige BioPharma Ltd
- PRG S&Tech Inc
- Qilu Pharmaceutical Co Ltd
- Radius Health Inc
- Rani Therapeutics LLC
- Regenerative Arthritis & Bone Medicine Inc
- Reliance Life Sciences Pvt Ltd
- Reven Holdings Inc
- Ribomic Inc
- Samsung Bioepis Co Ltd
- Sandoz International GmbH
- Shaanxi Micot Technology Co Ltd
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Celgen Bio-Pharmaceutical Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Mab Venture Biopharm Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shin Poong Pharm Co Ltd
- Stelis Biopharma Ltd
- Surrozen Inc
- Suzhou Stainwei Biotech Inc
- Taithera Inc
- Takeda Pharmaceutical Co Ltd
- Tempest Therapeutics Inc
- Teva Pharmaceutical Industries Ltd
- The National Institute for Biotechnology in the Negev Ltd
- The United Laboratories International Holdings Ltd
- Tritech Biopharmaceuticals Co Ltd
- TSH Biopharm Corporation Ltd
- Uni-Bio Science Group Ltd
- Vibe Pharmaceuticals LLC
- Vidasym Inc
- Viking Therapeutics Inc
- Wuxi Hebang Biotechnology Co Ltd
- Yooyoung Pharm Co Ltd
- Zosano Pharma Corp
- Zydus Lifesciences Ltd
- Osteoporosis – Drug Profiles
- (cholecalciferol + raloxifene) – Drug Profile
- 2-AMD – Drug Profile
- 3D-QM – Drug Profile
- 3D-QMS – Drug Profile
- 7-E – Drug Profile
- abaloparatide – Drug Profile
- acolbifene + prasterone – Drug Profile
- Aerami-701 – Drug Profile
- AGA-04 – Drug Profile
- AGA-2118 – Drug Profile
- alendronate sodium – Drug Profile
- ALX-0141 – Drug Profile
- Aptamers to Inhibit Sclerostin for Osteoporosis – Drug Profile
- ATI-2231 – Drug Profile
- B-104 – Drug Profile
- Bi-specific Monoclonal Antibody to Activate FRP and LRP for Bone Fracture and Osteoporosis – Drug Profile
- blosozumab – Drug Profile
- Bmab-1000 – Drug Profile
- calcitonin DR – Drug Profile
- Caviunin – Drug Profile
- CD-030 – Drug Profile
- CDRI-99/373 – Drug Profile
- CG-002 – Drug Profile
- CGN-001 – Drug Profile
- cholecalciferol + risedronate sodium – Drug Profile
- CLZ-1001 – Drug Profile
- dehydrodiconiferyl alcohol – Drug Profile
- denosumab – Drug Profile
- denosumab biosimilar – Drug Profile
- DKF-334 – Drug Profile
- Draxin – Drug Profile
- Drug for Osteoporosis – Drug Profile
- Drugs to Agonize GIP and GLP-2 for Osteoporosis – Drug Profile
- Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia – Drug Profile
- Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders – Drug Profile
- DWP-458 – Drug Profile
- DWP-820S003 – Drug Profile
- EB-613 – Drug Profile
- Ewha-18278 – Drug Profile
- Fusion Protein to Inhibit Activin A for Cancer Cachexia and Osteoporosis – Drug Profile
- GB-223 – Drug Profile
- GB-930 – Drug Profile
- genipin – Drug Profile
- GLPG-4399 – Drug Profile
- HI P. Goldsteinii – Drug Profile
- HS-200902 – Drug Profile
- HU-671 – Drug Profile
- IHBD-1 – Drug Profile
- IPS-02001 – Drug Profile
- JMT-103 – Drug Profile
- JS-008 – Drug Profile
- KER-012 – Drug Profile
- KKM-0805 – Drug Profile
- KKM-0902 – Drug Profile
- KN-012 – Drug Profile
- KY-273 – Drug Profile
- LEX-06 – Drug Profile
- Link_TSG6 – Drug Profile
- LX-001 – Drug Profile
- MES-1007 – Drug Profile
- minodronic acid – Drug Profile
- MMX – Drug Profile
- Monoclonal Antibodies to Inhibit Plexin-B1 and Sema4D for Oncology, Neurology and Metabolic Disorders – Drug Profile
- Monoclonal Antibody for Osteoporosis – Drug Profile
- Monoclonal Antibody to Antagonize FSH Receptor for Obesity and Osteoporosis – Drug Profile
- Monoclonal Antibody to Inhibit SOST for Osteoporosis – Drug Profile
- MT-1009 – Drug Profile
- NaQuinate – Drug Profile
- neridronic acid – Drug Profile
- NT-1801 – Drug Profile
- OFXO-11 – Drug Profile
- Oral Salt-Inducible Kinase (SIK) Inhibitors – Drug Profile
- Osteoporosis – Drug Profile
- Osteoporosis / Bone Fractures – Drug Profile
- OXY-153 – Drug Profile
- OXY-200 – Drug Profile
- parathyroid hormone – Drug Profile
- Peptide for osteoporosis – Drug Profile
- Peptides for Osteoporosis – Drug Profile
- PHN-031 – Drug Profile
- PRGS-4 – Drug Profile
- Protein to Antagonize PPAR Gamma-2 for Obesity, Alopecia, Osteoporosis and Rheumatoid Arthritis – Drug Profile
- RAB-001 – Drug Profile
- RBM-007 – Drug Profile
- Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis – Drug Profile
- Recombinant Protein 1 for Osteoporosis and Rheumatoid Arthritis – Drug Profile
- Recombinant Protein 2 for Osteoporosis and Rheumatoid Arthritis – Drug Profile
- Recombinant Protein 3 for Osteoporosis and Rheumatoid Arthritis – Drug Profile
- Recombinant Protein for Osteoporosis and Rheumatoid Arthritis – Drug Profile
- Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis – Drug Profile
- Recombinant Proteins to Antagonize CSF 1, ITGAV and ITGB3 for Osteoporosis – Drug Profile
- Recombinant Proteins to Target Betaglycan and ActRII for Obesity and Post Menopausal Osteoporosis – Drug Profile
- romosozumab – Drug Profile
- RPWH-1005a – Drug Profile
- S-0071500 – Drug Profile
- S-008399 – Drug Profile
- SAL-023 – Drug Profile
- SFX-01 – Drug Profile
- SHR-1222 – Drug Profile
- Small Molecule for Oncology, Psoriasis and Osteoporosis – Drug Profile
- Small Molecule to Activate sGC for Osteoporosis – Drug Profile
- Small Molecule to Agonize LGR4 for Oncology and Osteoporosis – Drug Profile
- Small Molecule to Agonize PTH-1R for Osteoporosis – Drug Profile
- Small Molecule to Antagonize OGR1 for Oncology and Osteoporosis – Drug Profile
- Small Molecule to Antagonize PTH for Oncology and Osteoporosis – Drug Profile
- Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis – Drug Profile
- Small Molecule to Inhibit Adrenomedullin for Post Menopausal Osteoporosis – Drug Profile
- Small Molecule to Inhibit BMX and BTK for Oncology and Osteoporosis – Drug Profile
- Small Molecule to Inhibit GPR183 for Epstein-Barr Viral Infections and Osteoporosis – Drug Profile
- Small Molecules 2 for Musculoskeletal, Gastrointestinal and Autoimmune Disorders – Drug Profile
- Small Molecules for Metabolic and Musculoskeletal Disorders – Drug Profile
- Small Molecules for Musculoskeletal and Metabolic Disorders – Drug Profile
- Small Molecules for Musculoskeletal, Gastrointestinal and Autoimmune Disorders – Drug Profile
- Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis – Drug Profile
- Small Molecules to Inhibit CXXC5 for Osteoporosis, Diabetes, Obesity, NASH and Wounds – Drug Profile
- Small Molecules to Inhibit DOCK5 for Bone Metastasis, Post Menopausal Osteoporosis and Rheumatoid Arthritis – Drug Profile
- Small Molecules to Inhibit Sclerostin for Osteoporosis – Drug Profile
- Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology – Drug Profile
- Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis – Drug Profile
- SP-35454 – Drug Profile
- SR-10171 – Drug Profile
- SR-2595 – Drug Profile
- Stem Cell Therapy for Osteoporosis – Drug Profile
- Synthetic Peptide for Obesity and Post Menopausal Osteoporosis – Drug Profile
- Synthetic Peptide for Osteoporosis and Bone Fracture – Drug Profile
- Synthetic Peptides for Ischemic Stroke, Osteoporosis, Sepsis and Psoriasis – Drug Profile
- Synthetic Peptides for Osteoporosis – Drug Profile
- Synthetic Peptides to Inhibit TRAF6 for Osteoporosis – Drug Profile
- TAI-1412 – Drug Profile
- TE-3110 – Drug Profile
- TE-3236 – Drug Profile
- teriparatide – Drug Profile
- teriparatide biosimilar – Drug Profile
- teriparatide LA – Drug Profile
- UCB-1 – Drug Profile
- VB-102 – Drug Profile
- VK-5211 – Drug Profile
- VS-105 – Drug Profile
- Y-001 – Drug Profile
- ZRC-3268 – Drug Profile
- Osteoporosis – Dormant Projects
- Osteoporosis – Discontinued Products
- Osteoporosis – Product Development Milestones
- Featured News & Press Releases
- Aug 10, 2022: Rani Therapeutics announces positive topline results from phase 1 study of RT-102 in osteoporosis
- Aug 08, 2022: Rani Therapeutics enters into $45 million loan agreement to support ongoing Ramipril platform advancement and clinical pipeline development
- Jul 20, 2022: Alvotech initiates a pharmacokinetic study for AVT03, a proposed biosimilar for Prolia and Xgeva
- Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
- Jul 18, 2022: Entera Bio announces execution of key regulatory milestones for EB613, the first oral anabolic drug proposed for the treatment of Osteoporosis; Miranda Toledano assumes CEO Position
- Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
- Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
- Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
- May 03, 2022: Rani Therapeutics’ RaniPill capsule named winner in the Health category of fast company’s 2022 World Changing Ideas Awards
- Apr 29, 2022: Transcenta doses first subject in Phase I osteoporosis drug trial in China
- Apr 01, 2022: Thousands of people set to benefit from first new treatment for osteoporosis for over a decade
- Mar 23, 2022: Rani Therapeutics announces initiation of phase 1 study of RT-102 oral PTH for osteoporosis
- Mar 10, 2022: Amgen keeps dominating Korea’s osteoporosis treatment market
- Mar 01, 2022: Radius Health files sNDA for TYMLOS in Men with osteoporosis
- Feb 17, 2022: Entera Bio to present at Aegis Virtual Conference on February 23rd
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Osteoporosis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Universities/Institutes, 2022
- Table 10: Products under Development by Companies, 2022
- Table 11: Products under Development by Companies, 2022 (Contd..1)
- Table 12: Products under Development by Companies, 2022 (Contd..2)
- Table 13: Products under Development by Companies, 2022 (Contd..3)
- Table 14: Products under Development by Companies, 2022 (Contd..4)
- Table 15: Products under Development by Companies, 2022 (Contd..5)
- Table 16: Products under Development by Companies, 2022 (Contd..6)
- Table 17: Products under Development by Companies, 2022 (Contd..7)
- Table 18: Products under Development by Companies, 2022 (Contd..8)
- Table 19: Products under Development by Companies, 2022 (Contd..9)
- Table 20: Products under Development by Universities/Institutes, 2022
- Table 21: Number of Products by Stage and Target, 2022
- Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 23: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 24: Number of Products by Stage and Mechanism of Action, 2022
- Table 25: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 26: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 27: Number of Products by Stage and Route of Administration, 2022
- Table 28: Number of Products by Stage and Molecule Type, 2022
- Table 29: Osteoporosis – Pipeline by Abiogen Pharma SpA, 2022
- Table 30: Osteoporosis – Pipeline by Ablynx NV, 2022
- Table 31: Osteoporosis – Pipeline by Abreos Biosciences Inc, 2022
- Table 32: Osteoporosis – Pipeline by Aclaris Therapeutics Inc, 2022
- Table 33: Osteoporosis – Pipeline by Addpharma Inc, 2022
- Table 34: Osteoporosis – Pipeline by Aerami Therapeutics Inc, 2022
- Table 35: Osteoporosis – Pipeline by Affilogic SAS, 2022
- Table 36: Osteoporosis – Pipeline by AgeX Therapeutics Inc, 2022
- Table 37: Osteoporosis – Pipeline by Airsea (Taizhou) Pharmaceutical Ltd, 2022
- Table 38: Osteoporosis – Pipeline by AlphaMab Co Ltd, 2022
- Table 39: Osteoporosis – Pipeline by Alvotech SA, 2022
- Table 40: Osteoporosis – Pipeline by Amgen Inc, 2022
- Table 41: Osteoporosis – Pipeline by Amogen Pharma Pvt Ltd, 2022
- Table 42: Osteoporosis – Pipeline by Angitia Biopharmaceuticals, 2022
- Table 43: Osteoporosis – Pipeline by Aryogen Pharmed Co, 2022
- Table 44: Osteoporosis – Pipeline by Aveta Biomics Inc, 2022
- Table 45: Osteoporosis – Pipeline by Bainan Biotech ApS, 2022
- Table 46: Osteoporosis – Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
- Table 47: Osteoporosis – Pipeline by Beijing Northland Biotech Co Ltd, 2022
- Table 48: Osteoporosis – Pipeline by Beryl Therapeutics Inc, 2022
- Table 49: Osteoporosis – Pipeline by Better Life Pharmaceuticals Inc, 2022
- Table 50: Osteoporosis – Pipeline by Biocon Ltd, 2022
- Table 51: Osteoporosis – Pipeline by Bone Biologics Corp, 2022
- Table 52: Osteoporosis – Pipeline by Cellatoz Therapeutics Inc, 2022
- Table 53: Osteoporosis – Pipeline by Celltrion Inc, 2022
- Table 54: Osteoporosis – Pipeline by China NT Pharma Group Co Ltd, 2022
- Table 55: Osteoporosis – Pipeline by ChoDang Pharm Co Ltd, 2022
- Table 56: Osteoporosis – Pipeline by Citragen Pharmaceuticals Inc, 2022
- Table 57: Osteoporosis – Pipeline by CK Regeon Inc, 2022
- Table 58: Osteoporosis – Pipeline by Clayton Biotechnologies Inc, 2022
- Table 59: Osteoporosis – Pipeline by Clonz Biotech Pvt Ltd, 2022
- Table 60: Osteoporosis – Pipeline by Corium Inc, 2022
- Table 61: Osteoporosis – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 62: Osteoporosis – Pipeline by Curexsys GmbH, 2022
- Table 63: Osteoporosis – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 64: Osteoporosis – Pipeline by Dongkook Pharmaceutical Co Ltd, 2022
- Table 65: Osteoporosis – Pipeline by Eden Biologics Inc, 2022
- Table 66: Osteoporosis – Pipeline by Eli Lilly and Co, 2022
- Table 67: Osteoporosis – Pipeline by Endoceutics Inc, 2022
- Table 68: Osteoporosis – Pipeline by Enesi Pharma Ltd, 2022
- Table 69: Osteoporosis – Pipeline by Entera Bio Ltd, 2022
- Table 70: Osteoporosis – Pipeline by Enteris BioPharma Inc, 2022
- Table 71: Osteoporosis – Pipeline by Enzene Biosciences Ltd, 2022
- Table 72: Osteoporosis – Pipeline by Enzo Biochem Inc, 2022
- Table 73: Osteoporosis – Pipeline by Epygen Biotech Pvt Ltd, 2022
- Table 74: Osteoporosis – Pipeline by Evgen Pharma Plc, 2022
- Table 75: Osteoporosis – Pipeline by Fresenius Kabi SwissBioSim GmbH, 2022
- Table 76: Osteoporosis – Pipeline by Galapagos NV, 2022
- Table 77: Osteoporosis – Pipeline by Gbiologics Inc, 2022
- Table 78: Osteoporosis – Pipeline by Gedeon Richter Plc, 2022
- Table 79: Osteoporosis – Pipeline by Genor BioPharma Co Ltd, 2022
- Table 80: Osteoporosis – Pipeline by Genu Pharma Co Ltd, 2022
- Table 81: Osteoporosis – Pipeline by GlycoNex Inc, 2022
- Table 82: Osteoporosis – Pipeline by GPN Therapeutics Inc, 2022
- Table 83: Osteoporosis – Pipeline by Haoma Medica Ltd, 2022
- Table 84: Osteoporosis – Pipeline by Helixmith Co Ltd, 2022
- Table 85: Osteoporosis – Pipeline by Histide AG, 2022
- Table 86: Osteoporosis – Pipeline by HNB Therapeutics LLC, 2022
- Table 87: Osteoporosis – Pipeline by Hualan Biological Engineering Inc, 2022
- Table 88: Osteoporosis – Pipeline by Huons Global Co Ltd, 2022
- Table 89: Osteoporosis – Pipeline by IMGENEX India Pvt Ltd, 2022
- Table 90: Osteoporosis – Pipeline by Immunwork Inc, 2022
- Table 91: Osteoporosis – Pipeline by InnoPharmaScreen Inc, 2022
- Table 92: Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd, 2022
- Table 93: Osteoporosis – Pipeline by Ipsen SA, 2022
- Table 94: Osteoporosis – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
- Table 95: Osteoporosis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 96: Osteoporosis – Pipeline by Jiangsu T-mab BioPharma Co Ltd, 2022
- Table 97: Osteoporosis – Pipeline by Keros Therapeutics Inc, 2022
- Table 98: Osteoporosis – Pipeline by Kyoto Pharmaceutical Industries Ltd, 2022
- Table 99: Osteoporosis – Pipeline by Lactocore Inc, 2022
- Table 100: Osteoporosis – Pipeline by LBL Biotech Corp, 2022
- Table 101: Osteoporosis – Pipeline by Lead Discovery Center GmbH, 2022
- Table 102: Osteoporosis – Pipeline by LEXEO Therapeutics LLC, 2022
- Table 103: Osteoporosis – Pipeline by Link Biologics Ltd, 2022
- Table 104: Osteoporosis – Pipeline by Lupin Ltd, 2022
- Table 105: Osteoporosis – Pipeline by Luye Pharma Group Ltd, 2022
- Table 106: Osteoporosis – Pipeline by Mabxience Holding SL, 2022
- Table 107: Osteoporosis – Pipeline by Max Biopharma Inc, 2022
- Table 108: Osteoporosis – Pipeline by Merck & Co Inc, 2022
- Table 109: Osteoporosis – Pipeline by Mesentech Inc, 2022
- Table 110: Osteoporosis – Pipeline by Mezomax Inc, 2022
- Table 111: Osteoporosis – Pipeline by Nano Intelligent Biomedical Engineering Corp, 2022
- Table 112: Osteoporosis – Pipeline by Nanomedic Inc, 2022
- Table 113: Osteoporosis – Pipeline by NeuClone Pty Ltd, 2022
- Table 114: Osteoporosis – Pipeline by NovMetaPharma Co Ltd, 2022
- Table 115: Osteoporosis – Pipeline by Omeros Corp, 2022
- Table 116: Osteoporosis – Pipeline by Oncosimis Biotech Pvt Ltd, 2022
- Table 117: Osteoporosis – Pipeline by Ortho Regenics Pvt Ltd, 2022
- Table 118: Osteoporosis – Pipeline by OssiFi Inc, 2022
- Table 119: Osteoporosis – Pipeline by Paras Biopharmaceuticals Finland Oy, 2022
- Table 120: Osteoporosis – Pipeline by PhytoHealth Corp, 2022
- Table 121: Osteoporosis – Pipeline by Prestige BioPharma Ltd, 2022
- Table 122: Osteoporosis – Pipeline by PRG S&Tech Inc, 2022
- Table 123: Osteoporosis – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 124: Osteoporosis – Pipeline by Radius Health Inc, 2022
- Table 125: Osteoporosis – Pipeline by Rani Therapeutics LLC, 2022
- Table 126: Osteoporosis – Pipeline by Regenerative Arthritis & Bone Medicine Inc, 2022
- Table 127: Osteoporosis – Pipeline by Reliance Life Sciences Pvt Ltd, 2022
- Table 128: Osteoporosis – Pipeline by Reven Holdings Inc, 2022
- Table 129: Osteoporosis – Pipeline by Ribomic Inc, 2022
- Table 130: Osteoporosis – Pipeline by Samsung Bioepis Co Ltd, 2022
- Table 131: Osteoporosis – Pipeline by Sandoz International GmbH, 2022
- Table 132: Osteoporosis – Pipeline by Shaanxi Micot Technology Co Ltd, 2022
- Table 133: Osteoporosis – Pipeline by Shandong New Time Pharmaceutical Co Ltd, 2022
- Table 134: Osteoporosis – Pipeline by Shanghai Celgen Bio-Pharmaceutical Co Ltd, 2022
- Table 135: Osteoporosis – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
- Table 136: Osteoporosis – Pipeline by Shanghai Henlius Biotech Inc, 2022
- Table 137: Osteoporosis – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 138: Osteoporosis – Pipeline by Shanghai Mab Venture Biopharm Co Ltd, 2022
- Table 139: Osteoporosis – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
- Table 140: Osteoporosis – Pipeline by Shin Poong Pharm Co Ltd, 2022
- Table 141: Osteoporosis – Pipeline by Stelis Biopharma Ltd, 2022
- Table 142: Osteoporosis – Pipeline by Surrozen Inc, 2022
- Table 143: Osteoporosis – Pipeline by Suzhou Stainwei Biotech Inc, 2022
- Table 144: Osteoporosis – Pipeline by Taithera Inc, 2022
- Table 145: Osteoporosis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 146: Osteoporosis – Pipeline by Tempest Therapeutics Inc, 2022
- Table 147: Osteoporosis – Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Table 148: Osteoporosis – Pipeline by The National Institute for Biotechnology in the Negev Ltd, 2022
- Table 149: Osteoporosis – Pipeline by The United Laboratories International Holdings Ltd, 2022
- Table 150: Osteoporosis – Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022
- Table 151: Osteoporosis – Pipeline by TSH Biopharm Corporation Ltd, 2022
- Table 152: Osteoporosis – Pipeline by Uni-Bio Science Group Ltd, 2022
- Table 153: Osteoporosis – Pipeline by Vibe Pharmaceuticals LLC, 2022
- Table 154: Osteoporosis – Pipeline by Vidasym Inc, 2022
- Table 155: Osteoporosis – Pipeline by Viking Therapeutics Inc, 2022
- Table 156: Osteoporosis – Pipeline by Wuxi Hebang Biotechnology Co Ltd, 2022
- Table 157: Osteoporosis – Pipeline by Yooyoung Pharm Co Ltd, 2022
- Table 158: Osteoporosis – Pipeline by Zosano Pharma Corp, 2022
- Table 159: Osteoporosis – Pipeline by Zydus Lifesciences Ltd, 2022
- Table 160: Osteoporosis – Dormant Projects, 2022
- Table 161: Osteoporosis – Dormant Projects, 2022 (Contd..1)
- Table 162: Osteoporosis – Dormant Projects, 2022 (Contd..2)
- Table 163: Osteoporosis – Dormant Projects, 2022 (Contd..3)
- Table 164: Osteoporosis – Dormant Projects, 2022 (Contd..4)
- Table 165: Osteoporosis – Dormant Projects, 2022 (Contd..5)
- Table 166: Osteoporosis – Dormant Projects, 2022 (Contd..6)
- Table 167: Osteoporosis – Dormant Projects, 2022 (Contd..7)
- Table 168: Osteoporosis – Dormant Projects, 2022 (Contd..8)
- Table 169: Osteoporosis – Dormant Projects, 2022 (Contd..9)
- Table 170: Osteoporosis – Discontinued Products, 2022
- Table 171: Osteoporosis – Discontinued Products, 2022 (Contd..1)
- List of Figures
- Figure 1: Number of Products under Development for Osteoporosis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.